AIDASH
17.1.2023 09:31:43 CET | Business Wire | Press release
The majority of businesses will struggle to meet net-zero goals without the use of carbon credits, but a lack of trust in the tool is stalling uptake and pushing corporate net-zero plans off track. This is one of the striking findings from a global survey of over 500 senior sustainability officers, commissioned by AiDash, a leading provider of vegetation management and other satellite- and AI-powered operations, maintenance, and sustainability solutions.
The ‘Carbon Offsetting in 2023’ study shows sustainability and carbon management are now mainstream concerns, with 97% of businesses including them in investment decisions, 79% of CSO’s already accountable to their boards or the public, 98% doing more than legally required to reduce emissions and 56% of businesses committed to net-zero targets on or before 2030.
However, over half of businesses (56%) do not have operational control over the majority of their greenhouse gas (GHG) emissions and nearly half (43%) use carbon offsets for hard-to-reduce GHG emissions alongside direct measures. As a result, many businesses cannot meet net-zero targets without the use of carbon credits.
Despite this critical need, the survey revealed a major lack of trust in carbon offsetting, with 41% of CSOs stating they do not use carbon credits as they do not adequately trust them. This comes at a time when many carbon offsetting projects are being shown to be inconsistently measured, inadequately monitored, and frequently failing to prove they are based on additional carbon captured.
Another revelation is the inconsistency in validation methods for carbon credits. 4% do not validate credits at all, 35% only buy from government or voluntary certified schemes, 43% are exploring working with credit rating agencies, 35% undertake their own validation or third-party due diligence and 41% use a combination of these methods. This lack of uniformity raises doubts surrounding the accuracy and comparability of corporate sustainability measurements.
With 89% of CSOs confirming they use KPI metrics to track the progress of their sustainability plans, it is essential that those metrics are watertight. However, the three biggest challenges to meeting net-zero goals are all data related:
- Collating reference data such as regional electricity and airline emissions factors (26%)
- Lack of common reporting frameworks (19%)
- Difficulty collating internal information (18%)
“Rather than waiting for governments to agree to regional or global frameworks, businesses are forging forward independently, making ambitious environmental commitments,” says Abhishek Vinod Singh, CEO, AiDash. “The intent and action is there but what these businesses desperately need is an organizational tool they can trust to accurately measure, monitor, track and validate the progress of their sustainability plans on their journey to net-zero.”
Carbon offsetting was not the only hot topic of the survey. It also revealed that CSOs are turning their eyes towards biodiversity. While only 24% currently include biodiversity impact in their sustainability strategies, 66% already have a role dedicated to biodiversity, with a substantial proportion intending to introduce one in the next two years. However, as it stands, legacy approaches to measuring biodiversity could hamper progress.
“Advances in satellite and AI technology can solve the vast majority of issues businesses are having collecting, analyzing and verifying their sustainability data,” continues Singh. “Our carbon solution not only provides measurements that meet carbon credit standards, but also continuous evidence to prove that credits are based on additional carbon captured and that carbon remains permanently in the ground, which is crucial for credible ESG reporting. By supporting how businesses apply carbon offsetting to their own land, we can save them up to 90% when compared with buying the equivalent from an escalating carbon credit market.
“For biodiversity, our solution can measure a host of complex environmental assets, allowing businesses to enhance natural capital metrics such as pollination, recreational benefits, and the value of food production. By analyzing 1,000s of sites in a matter of weeks, and utilizing one ecologist to verify the data captured, the AiDash solution can reduce biodiversity management operational expenditure by up to 75%, helping businesses adhere to impending legislation in the US, Europe, and UK.”
To download the complete survey results, visit https://www.aidash.com/resource/carbon-offsets-report-2023/
About AiDash
AiDash is an AI-first vertical SaaS company on a mission to transform operations, maintenance, and sustainability in industries with geographically distributed assets by using satellites and AI at scale. With access to a continual, near real-time stream of critical data, utilities, energy, mining, and other core industries can make more informed decisions and build optimized long-term plans, all while reducing costs, improving reliability, and achieving sustainability goals. To learn more about how AiDash is helping core industries become more resilient, efficient, and sustainable, visit www.aidash.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005064/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
